Drugging the Undruggable.

There’s a revolution unfolding in cancer therapeutics as researchers learn to harness the immune system to fight even the most stubborn tumors.

IBF joins Nectin Therapeutics Series A Round

Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors.

Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

The merger would result in a combined company that will focus predominantly on the development and commercialization of Ayala’s lead program AL102 for the treatment of desmoid tumors and Advaxis’s candidate ADXS-504 in development for prostate cancer.